Latest filing published 18 Aug 2026 for BridgeBio Pharma, Inc., €325k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Maricel Apuli is a declared insider of BridgeBio Pharma, Inc., with filings sourced from SEC (Form 4). The record holds 13 filings, for trades running from 19 March 2025 to 16 August 2026.
The open-market record consists of 5 sales worth €453k, with no purchase. Outside the open market, there are 8 share grants. Since January 2026: no purchases and 2 sales on the market.
On 18 August 2026 came the latest disclosure, a share grant for €325k in BridgeBio Pharma, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations